
Medical Properties Trust (MPT) returned to profitability in the first quarter of 2026, reporting US$252.07 million in revenue and net income of US$32.83 million, after a net loss in the same period last year.
See our latest analysis for Medical Properties Trust.
The stronger first quarter numbers and return to profitability appear to have supported a short term rebound, with a 7 day share price return of 7.89% and 30 day share price return of 14.13%. This has occurred even though the 3 year total shareholder return of 17.53% and 5 year total shareholder return of 60.97% signal longer term value erosion and fading momentum over that period.
If this earnings reset has you rethinking your portfolio, it can be helpful to widen the lens beyond hospital real estate and check out 18 top founder-led companies
With MPT trading at US$5.33, sitting at a discount to both one estimate of intrinsic value and the average analyst price target, you have to ask: is there real upside here, or is the market already pricing in future growth?
With Medical Properties Trust last closing at $5.33 against a widely followed fair value estimate of $5.79, the current narrative centers on balance sheet repair, earnings recovery, and what investors are willing to pay for those future cash flows.
Analysts expect earnings to reach $87.0 million (and earnings per share of $0.69) by about May 2029, up from $126.8 million loss today. In order for the above numbers to justify the price target of the analysts, the company would need to trade at a P/E ratio of 55.4x on those 2029 earnings, compared to 23.7x on a loss-making basis today.
Want to see what sits behind that earnings swing and rich future multiple? The narrative leans heavily on margin repair, modest revenue assumptions, and a higher valuation bar that only detailed cash flow work really explains.
Result: Fair Value of $5.79 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the narrative still leans on resolving distressed tenants and managing higher interest costs, and setbacks on either front could quickly challenge today’s optimism.
Find out about the key risks to this Medical Properties Trust narrative.
If you are unsure how you feel about the story so far, you can take a closer look at the company’s balance of risks and rewards by reviewing 3 key rewards and 2 important warning signs
If you stop at MPT, you could miss out on stocks that better fit your goals, so put a few powerful screeners to work for you today.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com